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Background: The B-type or brain natriuretic peptides
(BNP) and the amino-terminal probrain natriuretic pep-
tide (NT-proBNP) are good markers of prognosis and
diagnosis in chronic heart failure (HF). It is unclear,
however, whether differences in their biological charac-
teristics modify their clinical correlates and prognostic
performance in HF. This work aimed to provide a direct
comparison of the prognostic value of BNP and NT-
proBNP in patients with chronic and stable HF.
Methods: We measured BNP and NT-proBNP at base-
line in 3916 patients enrolled in the Valsartan Heart
Failure Trial. To identify the variables associated with
both peptides, we conducted simple and multivariable
linear regression analyses. We used Cox multivariable
regression models to evaluate the independent prognos-
tic value for all-cause mortality, mortality and morbid-
ity, and hospitalization for HF. Prognostic performance
was assessed by pairwise comparisons of the area under
the curve of receiver-operator characteristic curves.
Results: NT-proBNP and BNP had similar relationships
with age, left ventrical ejection fraction, and internal
diameter and creatinine clearance. Either peptide
ranked as the first independent predictor of outcome
after adjustment for major confounding clinical charac-
teristics. ROC curves were almost superimposable for
all-cause mortality (area under the curve (SE): BNP
0.665 (0.011) vs NT-proBNP 0.679 (0.011); P 0.0734), but
NT-proBNP was superior to BNP for predicting mortal-
ity and morbidity (P  0.032) or hospitalization for HF
(P  0.0143). Overall sensitivity and specificity ranged
from 0.590 to 0.696.
Conclusions: The natriuretic peptides BNP and NT-
proBNP showed subtle differences in their relation to
clinical characteristics and prognostic performance in a
large population of patients with chronic and stable HF.
They were the most powerful independent markers of
outcome in HF.
© 2006 American Association for Clinical Chemistry
The B-type or brain natriuretic peptides (BNP) are good
markers of prognosis and for diagnosis of chronic heart
failure (HF)8 (1, 2). It has been suggested that they may be
useful as surrogate markers of therapeutic efficacy in
clinical trials of patients with chronic HF (3, 4).
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BNP and the amino-terminal fragment of BNP (pro-
hormone NT-proBNP) are secreted in equimolar amounts
in response to mechanical or neurohormonal stimulation.
Both peptides are reliably measured in clinical practice.
Whereas BNP is a natriuretic and diuretic hormone, the
biological role of NT-proBNP, if any, is not well under-
stood. These peptides also differ with regard to their
biological half-life, in vitro stability, and mechanisms
involved in their clearance (5 ). However, there is no
compelling evidence in favor of either peptide in terms of
indicators of clinical severity (6–8), screening for left
ventricular (LV) dysfunction in the general population
(9 ), diagnosis (10–13), or prognosis (8, 14, 15). In partic-
ular, a study in a large and representative population of
patients with chronic HF is required to examine and
compare the prognostic value of BNP and NT-proBNP in
a setting that would allow sufficient statistical power to
examine subgroups of patients according to their clinical
characteristics.
In the Valsartan Heart Failure (Val-HeFT) trial, blood
samples were collected at the time of entry into the study
in a large population of patients with chronic and symp-
tomatic HF, yielding one of the largest plasma banks
collected for this disease. The clinical utility of several
neurohormones, including BNP, has already been evalu-
ated in this trial (16–19). In this study, we carried out a
direct comparison of the 2 natriuretic peptides in this
large population in relation to the severity of the disease
and clinical outcome.
Materials and Methods
study design and patients
Val-HeFT was a randomized, placebo-controlled, double-
blind, parallel-arm multicenter trial. A total of 5010 pa-
tients with stable, symptomatic HF, who were on pre-
scribed HF therapy and who had LV ejection fraction
(LVEF) of 40% and LV diameter in diastole adjusted for
body surface area (LVIDd/BSA) of 2.9 cm/m2, were
enrolled in the study. Results of the main trial have been
presented in detail previously (20 ).
measurement of natriuretic peptide
concentrations
Blood samples were collected at study entry by venipunc-
ture in evacuated plastic tubes containing EDTA dipotas-
sium salt. Blood samples were centrifuged at 3500g for 10
min at 4 °C immediately after collection, and plasma
samples were stored at 70 °C. BNP (IRMA Shionogi)
and NT-proBNP (ECLIA Elecsys 2010 analyzer, Roche
Diagnostics) were measured by commercially available
assays in plasma samples never thawed before. Norepi-
nephrine, plasma renin activity, and C-reactive protein
were determined, as previously described (17, 19). The
intraassay CVs were 2.9% and 3.9% for NT-proBNP and
BNP, respectively. Corresponding interassay CVs were
3.9% and 4.7%. In 81 age-matched, healthy volunteers, the
95th percentile concentrations were 121 and 76 ng/L, for
NT-proBNP and BNP, respectively.
statistical methods
We performed all statistical analyses both NT-proBNP
and BNP concentrations measured at baseline in all pa-
tients (n  3916). We compared concentrations of NT-
proBNP or BNP according to clinical characteristics by
means of the Wilcoxon rank-sum test because the normal-
ity of the distribution was not satisfied. We assessed the
correlation between baseline concentrations of BNP and
NT-proBNP with the Pearson correlation coefficient test.
Simple linear regression analyses were carried out to
evaluate the relationship between baseline concentrations
of BNP or NT-proBNP (expressed as log-transformed
data) and clinical characteristics as continuous variables
when appropriate. The assumptions underlying the linear
regression models, such as linearity, normality, and ho-
moscedasticity, were satisfied for all the independent
continuous variables, except for creatinine and bilirubin,
which were transformed on a logarithmic scale.
Multivariable linear regression analyses were carried
out to determine the variables independently associated
with NT-proBNP or BNP, expressed as continuous log-
transformed concentrations. In the final models, only
variables statistically significant at the univariate analysis
(P 0.05) were included.  regression coefficients and
their significance from multiple linear regression analysis
are reported.
The relationship between NT-proBNP or BNP and
these variables was also explored by dividing them into
quartiles and assessing differences by means of the
Kruskal–Wallis test.
Cox multivariable regression models were used to
evaluate the independent prognostic value of baseline
NT-proBNP and BNP (entered as categorical variables
below and above the median concentration) on all-cause
mortality, on mortality and morbidity (M&M), and on
hospitalization for HF alone. Mean follow-up time was 23
months. The model included all the demographic, clinical,
and echocardiographic variables, considered as categori-
cal, that had a significant univariate relationship with
outcome. To check for possible biases resulting from the
arbitrary choice of median concentration, we also carried
out the same Cox multivariate analysis with continuous
variables where appropriate. We checked the assumption
of proportional hazard with the log[-log(survival)] plot
and by the time-dependent covariate test. Also, we used
the martingale residuals plot to evaluate whether a spe-
cific time-independent continuous covariate might be
entered directly into the model, or if a transformation was
necessary. To ease the interpretability of these results,
hazard ratios have been computed for intervals of 50
ng/L of BNP and 500 ng/L of NT-proBNP.
To assess the incremental prognostic value of NT-
proBNP or BNP with respect to clinical variables, we
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evaluated a separate addition of NT-proBNP or BNP to a
model based on demographic, clinical, and echocardio-
graphic variables with the likelihood-ratio test with 1
degree of freedom.
To compare the predictive value of BNP and NT-
proBNP, ROC curves were generated for the main out-
comes. Exploratory analyses were also carried out to
compare the prognostic value of both natriuretic peptides
for the 2 main adjudicated causes of death, sudden death
from cardiac causes and death because of pump failure
(20 ). Pairwise comparisons of the areas under the curve
(AUC) were conducted, following the procedure of Han-
ley and McNeil (21 ).
All endpoints were adjudicated by an independent
Endpoint Committee, blind to study treatment. All tests
were made at a 2-sided, 5% significance level. Statistical
Table 1. Plasma concentrations of NT-proBNP or BNP according to baseline clinical characteristics.
Variable Category, n NT-proBNP, n (ng/L) P valuea BNP, n (ng/L) P valuea
Overall (n  3916) 895 (375–1985) 99 (41–242)
Age, years (n) 70 (2767) 721 (300–1547) 0.0001 82 (34–204) 0.0001
70 (1149) 1477 (706–2883) 156 (68–313)
Sex Females (777) 984 (406–2291) 0.0147 95 (36–229) 0.1129
Males (3139) 876 (368–1940) 100 (42–245)
NYHA II (2412) 745 (318–1553) 0.0001 84 (36–189) 0.0001
III (1423) 1194 (516–2767) 132 (50–315)
IV (77) 2379 (904–5332) 261 (98–629)
LVIDD, cm 6.8 (1818) 740 (301–1721) 0.0001 78 (33–196) 0.0001
6.8 (2098) 1029 (459–2181) 123 (51–272)
LVEF, % 27 (2054) 674 (292–1495) 0.0001 80 (33–182) 0.0001
27 (1860) 1172 (523–2524) 134 (54–303)
BMI, kg/m2 22 (3504) 827 (355–1816) 0.0001 95 (39–223) 0.0001
22 (412) 1728 (793–3620) 194 (58–407)
Diabetes No (2887) 858 (357–1937) 0.0037 94 (39–238) 0.0081
Yes (1029) 984 (426–2189) 114 (49–249)
Atrial fibrillation No (3450) 799 (338–1819) 0.0001 93 (38–234) 0.0001
Yes (466) 1596 (912–3141) 141 (72–286)
Ischemic etiology No (1653) 859 (322–1978) 0.0114 84 (28–218) 0.0001
Yes (2263) 916 (404–1988) 110 (51–254)
Background therapy
Diuretics No (591) 528 (259–1073) 0.0001 64 (31–126) 0.0001
Yes (3325) 976 (412–2175) 110 (43–258)
Digoxin No (1246) 726 (335–1592) 0.0001 90 (41–223) 0.0568
Yes (2670) 987 (399–2141) 105 (41–250)
ACE inhibitor No (269) 885 (369–1956) 0.0070 98 (40–240) 0.0197
Yes (3647) 1081 (471–2389) 119 (54–272)
Beta-blockers No (2490) 948 (384–2075) 0.0006 104 (41–247) 0.2403
Yes (1426) 796 (355–1753) 93 (41–232)
Sitting SBP, mm Hg 121 (1982) 811 (359–1801) 0.0001 91 (37–244) 0.0002
121 (1934) 974 (391–2159) 109 (44–260)
Sitting heart rate, bpm 72 (1717) 812 (359–1816) 0.0008 101 (42–234) 0.9263
72 (2199) 941 (385–2138) 98 (39–248)
Bilirubin, mol/L 10.26 (1713) 665 (309–1425) 0.0001 76 (33–173) 0.0001
10.26 (2196) 1113 (471–2411) 129 (49–296)
Creatinine, mol/L 107 (1932) 665 (293–1418) 0.0001 76 (33–180) 0.0001
107 (1978) 1186 (502–2600) 134 (54–294)
Aldosterone, ng/L 101 (1897) 837 (359–1886) 0.0046 97 (42–234) 0.5986
101 (1952) 953 (391–2065) 102 (39–250)
PRA, ng/mL/h 5.26 (1917) 948 (407–2050) 0.0018 119 (52–272) 0.0001
5.26 (1975) 845 (341–1922) 82 (33–207)
Norepinephrine, ng/L 394 (1928) 731 (314–1501) 0.0001 78 (33–184) 0.0001
394 (1970) 1104 (469–2530) 129 (52–298)
CRP, mg/L 3.23 (1876) 755 (329–1627) 0.0001 86 (38–207) 0.0001
3.23 (1915) 1057 (430–2404) 115 (44–278)
Concentrations presented as median (Q1-Q3).
a Wilcoxon rank-sum test.
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analyses were performed with SAS 8.2 (SAS Institute,
Inc.).
Results
baseline concentrations of nt-probnp and bnp
and association with clinical variables
The median (25th-75th percentiles) concentration of NT-
proBNP at baseline was 895 (375–1985) ng/L (n  3916).
Corresponding values for BNP were 99 ng/L (41–242).
Pearson coefficient of correlation between baseline con-
centrations of NT-proBNP and BNP was 0.77 (P 0.0001).
Plasma concentrations of NT-proBNP and BNP accord-
ing to baseline clinical characteristics are presented in
Table 1. NT-proBNP and BNP were significantly higher in
older patients, and in patients with more symptomatic
HF, more dilated LV and more severe LV dysfunction,
lower body mass index (BMI), lower sitting arterial blood
pressure, HF of ischemic etiology, or atrial fibrillation at
study entry. The concentration of both peptides was also
higher in patients with increased laboratory markers
(creatinine and bilirubin) and neurohormones (plasma
renin activity, norepinephrine, and C-reactive protein).
There were no relevant differences between the univariate
clinical correlates of NT-proBNP or BNP, except for
beta-blocker use, sitting heart rate, and plasma aldoste-
rone concentration (all nonsignificant for BNP).
Baseline log-transformed NT-proBNP or BNP concen-
trations correlated with age, LVEF, and LVIDd, with r2
ranging from 0.02 to 0.12 (P 0.0001, variables as contin-
uous data). Fig. 1 compares the relationship between
median NT-proBNP or BNP and these variables, catego-
rized by quartiles. The trend was similar for both natri-
uretic peptides.
The strongest continuous relationship was found be-
tween log-transformed estimated glomerular filtration
rate (eGFR) and NT-proBNP (Pearson CV 0.34, P
0.0001) or BNP (0.21, P 0.0001). The relationship
between median concentrations of NT-proBNP or BNP
and eGFR showed a steeper increase of NT-proBNP
compared with BNP in patients with reduced renal func-
tion (Fig. 2). However, the number of patients with eGFR
30 mL/min/m2 was limited in this study (n  59, 1.5%
of the population).
The clinical variables that were independently associ-
ated with baseline concentrations of BNP or NT-proBNP
(expressed as log-transformed data) were largely com-
mon to both peptides, with the exception of the use of
angiotensin-converting enzyme (ACE) inhibitors and
beta-blockers (Table 2). Whereas NT-proBNP was inde-
pendently associated with ACE inhibitors (positive rela-
tion) and beta-blockers (negative relation), no such asso-
ciations were found with BNP. The factors with the
strongest association were age, ischemic etiology, pres-
ence of atrial fibrillation, LV ejection fraction, and internal
diameter.
Fig. 1. Median concentrations of baseline NT-proBNP and BNP by
quartiles of age, LVEF, and LVIDd.
Differences of median concentrations among quartiles were evaluated by the
Kruskal–Wallis test and were significant for age, LVEF, and LVIDd for both
peptides (all with P 0.00001). Vertical scale is different for NT-proBNP (black
bars) and BNP (white bars). The number of patients in each category is shown
above bars.
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prognostic value of bnp and nt-probnp
The adjusted hazard ratios for death, M&M, or hospital-
ization for HF according to baseline deciles of NT-proBNP
and BNP are presented in Fig. 3. There was a similar
progression in the probability of death with increasing
plasma concentration of NT-proBNP or BNP, with hazard
ratios in the tenth decile of 4.02 (2.63–6.11) and 4.02
(2.70–5.99), respectively. Corresponding values for M&M
were 4.74 (3.36–6.70) and 3.67 (2.70–4.98). An apparent
superiority of NT-proBNP over BNP for predicting the
risk of hospitalization for patients with HF was observed
across the whole range of concentrations. For instance, the
relative risk of hospitalization for HF was higher in the
tenth decile of NT-proBNP [7.51 (4.30–13.11)] compared
with that of BNP [3.86 (2.56–5.84)], although 95% confi-
dence intervals (CIs) always overlapped.
The independent prognostic values of baseline BNP or
NT-proBNP were tested separately in Cox multivariable
models that included the demographic, clinical, and echo-
cardiographic variables with a statistically significant
association with outcome at univariate analysis (P 0.05).
First, the natriuretic peptides and the other covariates
were entered as categorical variables, dichotomized above
or below the median value. In these models, NT-proBNP
was the first predictor of outcome with hazard ratios (95%
CI) of 2.07 (1.76–2.46) for mortality, 2.20 (1.92–2.51) for
M&M, and of 2.66 (2.19–3.22) for hospitalization for HF
(Fig. 4). Similarly, BNP resulted as the strongest indepen-
dent predictor of mortality [1.87 (1.59–2.20)], M&M [2.05
(180–2.34)], and hospitalization for HF [2.48 (2.06–2.98)].
When the natriuretic peptides and appropriate covariates
were considered as continuous variables, their prognostic
value was consistent with the analysis based on median
cutoff values. For instance, an increment of 500 ng/L of
baseline NT-proBNP concentration corresponded to an
increase of risk of 3.8% for mortality (P 0.0001), whereas
an increment of 50 ng/L of baseline BNP concentration
corresponded to an increase of risk of 5.7% (P 0.0001).
Similarly, increases of risk for M&M were 3.5% and 5.4%,
and 3.0% and 5.7% for hospitalization for HF, respectively
(P 0.0001 for all). Finally, the likelihood-ratio test
showed that BNP or NT-proBNP provided significant
incremental prognostic value for the prediction of all-
cause mortality, M&M, and hospitalization for HF (all
with P 0.0001) compared with a model based on demo-
graphic, echocardiographic, and clinical variables.
The predictive values of NT-proBNP and BNP were
compared by means of ROC curves (Table 3). The AUC
(SE) for NT-proBNP (0.679 [0.011]) was marginally higher
than for BNP (0.665 [0.001]; P  0.0734) for predicting
all-cause mortality. For M&M, NT-proBNP (AUC  0.688
[0.009]) had a statistically significant higher predictive
value than BNP [0.674 (0.009); P  0.0332]. The same was
Fig. 2. Median plasma concentrations of NT-proBNP and BNP according
to eGFR.
eGFR categories are based on the National Kidney Foundation classification of
renal function. Vertical scale is different for NT-proBNP (black bars) and BNP
(white bars). The number of patients in each category is shown above bars.
Table 2. Multivariable linear regression for the association with baseline loge NT-proBNP, or loge BNP.
Clinical variables loge NT-proBNP loge BNP
 regression coefficients (SE) P value  regression coefficients (SE) P value
Age (1 year) 0.0254 (0.0016) 0.0001 0.0183 (0.0020) 0.0001
BMI (1 kg/m2) 0.0637 (0.0036) 0.0001 0.0585 (0.0046) 0.0001
NYHA (III–IV) 0.2477 (0.0332) 0.0001 0.2086 (0.0420) 0.0001
LVEF (1%) 0.0300 (0.0024) 0.0001 0.0235 (0.0030) 0.0001
LVIDD (1 cm) 0.2052 (0.0185) 0.0001 0.2416 (0.0023) 0.0001
Ischemic etiology (yes) 0.2429 (0.0423) 0.0001
Atrial fibrillation (yes) 0.5416 (0.0509) 0.0001 0.2575 (0.0634) 0.0001
SBP (1 mmHg) 0.0029 (0.0011) 0.0109
Heart rate (1 bpm) 0.0087 (0.0013) 0.0001
Digoxin (yes) 0.1405 (0.0443) 0.0015
Diuretics (yes) 0.2343 (0.0455) 0.0001 0.2636 (0.0575) 0.0001
ACE inhibitors (yes) 0.1741 (0.0621) 0.0051
Beta-blockers (yes) 0.1419 (0.0340) 0.0001
Bilirubin (1 loge mol/L) 0.3601 (0.0330) 0.0001 0.4346 (0.0418) 0.0001
Creatinine (1 loge mol/L) 0.8119 (0.0747) 0.0001 0.4811 (0.0946) 0.0001
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true for hospitalization for HF [0.685 (0.011) vs 0.665
(0.012); P  0.0143]. For a given peptide, optimum cutoff
points were similar for main outcomes (Table 3). The
concentrations of BNP at 95% of sensitivity were 18, 17,
and 14 ng/L for mortality, M&M, and hospitalization for
HF, respectively (Table 3). Corresponding values for
NT-proBNP were 202, 208, and 250 ng/L. The concentra-
tions of BNP at 95% of specificity were 531, 490, and 546
ng/L for mortality, M&M, and hospitalization for HF,
respectively. Corresponding values for NT-proBNP were
4643, 4367, and 5015 ng/L. In exploratory analyses, the
prognostic values of both peptides were compared ac-
cording to adjudicated causes of death: whereas NT-
proBNP was similar to BNP in predicting sudden death
[399 events, AUC 0.619 (0.015) vs 0.627 (0.015); P 0.47,
Fig. 5], results superior to BNP for the prediction of death
from pump failure [191 events, AUC  0.749 (0.017) vs
0.703 (0.019); P  0.0003].
When patients were divided into clinical subgroups,
NT-proBNP retained statistical superiority over BNP in
males (P  0.018 for all-cause mortality; P  0.044 for
hospitalization for HF, Table 4), in patients older than 70
years (P 0.0001 for all-cause mortality; P  0.023 for
hospitalization for HF), or in patients with eGFR of 30 and
59 mL/min/1.73 m2 (P  0.017 for all-cause mortality;
P  0.036 for hospitalization for HF). BNP and NT-
proBNP, however, performed similarly in females, in
patients 70 years, in patients with eGFR 60–89 mL/
min/1.73 m2, in patients with or without diabetes, and in
3 classes of BMI index (Table 4).
Discussion
Our findings indicate that the hormone BNP and the
inactive amino terminal fragment NT-proBNP exhibited
parallel changes with age, LVEF, and LV diameter in
patients with chronic and symptomatic HF. These pep-
tides were the first independent predictors of outcome
after adjustment for major confounding baseline clinical
characteristics. However, a head-to-head comparison of
their prognostic value showed that NT-proBNP per-
formed slightly better than BNP in predicting outcome, in
particular for death from pump failure and hospitaliza-
tions for HF. These results were obtained in a large and
relatively heterogeneous population of well-characterized
patients enrolled in a multicenter international clinical
trial. They extend the results of several previous studies
performed on smaller cohorts of patients, and often in
single centers (7, 11–13, 15). The biological relevance of
the present observations will have to be confirmed in
different clinical and/or analytical settings.
relationships between nt-probnp, bnp, and
clinical severity
In this study we investigated the association of various
demographic, clinical, and echocardiographic variables
and baseline concentrations of natriuretic peptides with
univariate and multivariable models. We concluded that
the set of variables associated with plasma concentrations
of NT-proBNP or BNP was essentially the same, with the
exception of the use of ACE inhibitors and beta-blockers.
Fig. 3. Adjusted hazard ratios for outcome by deciles of baseline
concentrations of BNP or NT-proBNP.
Hazard ratio and 95% CI for BNP (open symbols) and NT-proBNP (closed
symbols), adjusted for clinical, demographic, and echocardiographic covariates
with significant univariate relationship with outcome (P0.05). The first decile of
each peptide is considered as the reference category. Number of patients for
each decile was 379 to 399.
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The reason for this difference is unknown at present;
however, recent studies have shown that the introduction
of a beta-blocker (metoprolol) in patients with mild and
stable HF raised the concentration of both C-terminal and
N-terminal natriuretic peptides (22–23). The strongest
associations were found with age, ischemic etiology of
Fig. 4. Prognostic models for all-cause mortality, M&M, and hospitalization for HF based on Cox proportional hazard regression.
Analysis adjusted for baseline NT-proBNP or BNP and the demographic, clinical, and echocardiographic variables with a significant univariate relationship with outcome
(P 0.05). Data presented as hazard ratio and 95% CIs in decreasing order of 2.
Table 3. Comparison of the prognostic performance of NT-proBNP and BNP for predicting outcome in patients with chronic
heart failure.
All-cause mortality, 758 events Mortality and morbidity, 1194 events Hospitalization for HF, 634 events
NT-proBNP BNP NT-proBNP BNP NT-proBNP BNP
Optimal prognostic value, ng/L 1016 125 1007 125 1007 126
AUC (SE) 0.679 (0.011) 0.665 (0.011) 0.688 (0.009) 0.674 (0.009) 0.685 (0.011) 0.665 (0.012)
P valuea 0.0734 0.0332 0.0143
Sensitivity 0.666 0.636 0.658 0.621 0.699 0.648
Concentration at 95% sensitivity, ng/L 202 18 208 17 250 14
Specificity 0.600 0.620 0.630 0.650 0.590 0.620
Concentration at 95% specificity, ng/L 4643 531 4367 490 5015 546
AUC: area under the curve.
a P value for the comparison of AUC according to the test of Hanley and McNeil (21).
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HF, presence of atrial fibrillation, LVEF, and LV internal
diameter, as previously described (24–26). Our data also
concur with the conclusion of a comparative study per-
formed in a large cohort of patients with stable ischemic
heart disease in which LVEF, age, and renal function were
the most powerful independent predictors of BNP and
NT-proBNP (8 ).
Among the continuous variables, the strongest associ-
ation was found with renal function. Median concentra-
tions of the natriuretic peptides increased progressively
with renal dysfunction estimated as eGFR and catego-
rized according to the classification of the National Kid-
ney Foundation. This trend has been observed in patients
presenting in emergency departments for dyspnea (27 ).
Decreased clearance from the kidney has been put for-
ward to explain increased BNP in patients with HF (28 ).
Although the mechanisms of elimination of these 2 pep-
tides might differ (BNP is mainly cleared by neutral
endopeptidases and specific receptors, whereas renal ex-
cretion is currently regarded as the main clearance mech-
anism for NT-proBNP (5 ), the increase of both peptides
with lower eGFR suggests that the susceptibility of NT-
proBNP concentrations to renal dysfunction was not,
apparently, greater than that of BNP. We must remember,
however, that the number of patients with severely com-
promised renal function (eGFR 30 mL/min/1.73 m2)
was limited in our study population, so this conclusion
does not apply in such patients. This extends to previous
Fig. 5. ROC curves for NT-proBNP and
BNP as markers of outcome.
NT-proBNP as bold continuous lines, BNP
as dashed lines.
Table 4. Comparison of the area under the ROC curves of NT-proBNP and BNP for predicting outcome in selected clinical
groups of patients with chronic heart failure.
Group Patients, n All-cause mortality Hospitalization for HF
NT-proBNP BNP P valuea NT-proBNP BNP P a
Age, 70 years 2767 0.670 (0.014) 0.680 (0.013) 0.29 0.707 (0.014) 0.697 (0.014) 0.32
Age, 70 years 1149 0.660 (0.018) 0.611 (0.019) 0.0001 0.619 (0.020) 0.587 (0.022) 0.023
Males 3139 0.684 (0.015) 0.665 (0.012) 0.018 0.0687 (0.013) 0.667 (0.013) 0.044
Females 777 0.662 (0.026) 0.667 (0.027) 0.81 0.671 (0.022) 0.665 (0.023) 0.70
eGFR 30–59 mL/min/1.73 m2 1660 0.682 (0.015) 0.656 (0.015) 0.017 0.656 (0.016) 0.635 (0.017) 0.036
eGFR 60–89 mL/min/1.73 m2 2012 0.650 (0.017) 0.657 (0.017) 0.60 0.674 (0.017) 0.661 (0.019) 0.22
Diabetes 1029 0.664 (0.020) 0.652 (0.020) 0.35 0.619 (0.020) 0.594 (0.021) 0.072
No diabetes 2887 0.683 (0.013) 0.669 (0.013) 0.14 0.707 (0.014) 0.669 (0.014) 0.40
BMI, 25 kg/m2 1353 0.687 (0.017) 0.663 (0.017) 0.044 0.593 (0.075) 0.668 (0.074) 0.16
BMI, 25–30 kg/m2 1734 0.678 (0.017) 0.661 (0.017) 0.17 0.656 (0.016) 0.635 (0.017) 0.099
BMI, 30 kg/m2 829 0.619 (0.027) 0.643 (0.026) 0.19 0.674 (0.017) 0.661 (0.019) 0.29
a P value for the comparison of AUC according to the test of Hanley and McNeil (21).
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observations of patients with myocardial infarction and
compensated renal dysfunction (7 ) and confirms recent
studies that showed similar renal extraction of the 2
peptides in healthy volunteers and in patients with essen-
tial arterial hypertension (29, 30).
prognostic value of nt-probnp and bnp in
heart failure
BNP and NT-proBNP are strong markers of outcome in
chronic HF (2, 17). The present analysis attests to their
superiority compared with other variables, but also con-
firms the strength of several clinical variables (older age,
diabetes, and lower LVEF) that have been powerful and
independent predictors of mortality and morbidity in a
large and contemporary population of patients with HF
(31 ). Few studies have directly compared the prognostic
value of the 2 brain natriuretic peptides in patients with
heart disease. Some have concluded that the 2 markers are
substantially equivalent (14, 15, 32). In patients with sta-
ble ischemic heart disease, Richards et al. (8 ) recently
showed that both peptides independently predicted a
composite clinical endpoint (1-year all-cause mortality or
admission with HF) with almost overlapping, event-free
survival curves. There are, however, some exceptions:
BNP (but not NT-proANP or NT-proBNP) independently
predicted sudden death in 382 patients with chronic HF
(33 ), whereas NT-proBNP (but not BNP) predicted symp-
tom-free survival and postoperative outcome in patients
with severe aortic stenosis (34 ). Differences have also
been observed in acute settings, for instance in response to
short term exercise (35 ) or after intravenous infusion of
Levosimendan (36 ). In the present study, NT-proBNP
performed better than BNP to predict death from pump
failure and hospitalization for HF (P  0.0003 and 0.0143
by univariate pairwise comparison, respectively). When
patients were divided into clinical subgroups, NT-
proBNP retained a statistical superiority over BNP in
males, in patients over 70 years, or with eGFR of 30 to 59
mL/min/1.73 m2. In univariate analysis, BNP and NT-
proBNP performed similarly in females, in patients 70
years, or in patients with eGFR 60 mL/min/1.73 m2. In
addition, the prognostic value of BNP and NT-proBNP
was similar in patients with or without diabetes and in
different classes of BMI (lean, overweight, or obese).
Several factors might, in principle, explain these differ-
ences. First, the longer estimated biological half-life of
NT-proBNP compared with BNP (70 min vs 20 min)
(37, 38) renders the former less prone to short-term fluc-
tuations that may confound the prognosis. This difference
is corroborated by the relatively smaller intraindividual
biological variation of NT-proBNP observed in patients
with HF (39 ). In the context of a large multicenter trial,
preanalytical deviations from the protocol during blood
collection, plasma processing, and storage would also
have a greater detrimental impact on BNP than on NT-
proBNP. Second, differences in the analytical perfor-
mance of the methods used to measure BNP and NT-
proBNP could influence their respective prognostic value,
although the impact of assay imprecision on the perfor-
mance of cardiac biomarkers for diagnosis seems not to be
critical (40 ). The IRMA used in the present study to
measure BNP showed slightly higher analytical variabil-
ity than the automated method for NT-proBNP; this could
further reduce the prognostic performance of BNP. It is
important to note that immunoreactive moiety detected
by any given immunoassay depends on the combined
influence of circulating forms of NT-proBNP and BNP,
the degree and rate at which they are degraded from
amino and/or C-terminals, and (most importantly) the
epitope(s) to which polyclonal or monoclonal antibodies
have been raised (41 ). Indeed, recent studies demon-
strated that the clinical results (including the reference
interval and decisional cutoff values) of BNP and NT-
proBNP assays are method-dependent (42 ). For these
reasons, the analytical performance and clinical accuracy
of any single immunoassay should be assessed in each
laboratory. Third, it cannot be excluded that different
relationships between NT-proBNP or BNP and some
clinical characteristics not considered in the present anal-
ysis might explain our data. Finally, the large study
population (3916) might have revealed subtle differences
in the prognostic performance of the 2 peptides not
detectable in smaller populations.
The relatively modest prognostic accuracy of BNP and
NT-proBNP in the present study (AUCs of 0.66 to 0.75,
sensitivity and specificity of 0.590 to 0.696) might result
from the fact that our population included only patients
with stable, chronic, and symptomatic mild-to-moderate
HF, with LV systolic dysfunction (LVEF 40%). Effective
neurohormone suppression with background therapy
might also have limited the prognostic performance of
these markers.
In conclusion, we report a small, but statistically signifi-
cant difference in the predictive value of 2 related natri-
uretic peptides in a well-characterized and large popula-
tion of patients with chronic and symptomatic HF.
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